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summary: A cost-effectiveness analysis of community-based HIV self-testing (HIVST) 
suggests that implementation is potentially cost-effective in Malawi. The scale-up of HIVST is 
suited to high HIV prevalence countries that target early diagnosis and initiation of anti-
retroviral treatment.  
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Abstract 
Background: HIV self-testing (HIVST) is effective, with scale-up underway in sub-Saharan 
Africa. We assessed cost-effectiveness of adding HIVST to existing facility-based HIV testing 
and counselling (HTC) services. Both 2010 (initiate at CD4<350 cells/μl) and 2015 (initiate all) 
WHO guidelines for antiretroviral treatment (ART) were considered.  
 
Methods: A microsimulation model was developed that evaluated cost-effectiveness, from 
both health provider and societal perspectives, of an HIVST service implemented in a cluster-
randomised trial (CRT) (ISRCTN02004005) in Malawi. The economic model drew upon health 
outcomes data observed in the CRT, and primary health economic studies undertaken in the 
trial population. Costs and health outcomes were evaluated over a 20-year time horizon, 
using a discount rate of 3%. Probabilistic sensitivity analysis was conducted to account for 
parameter uncertainty. 
 
Results: From the health provider perspective and 20-year time horizon, facility HTC using 
2010 WHO ART guidelines was the least costly (US$294.71 per person, 95%CrI:270.79-
318.45) and least effective (11.64 QALYs per person, 95%CrI:11.43-11.86) strategy. 
Compared to this strategy, the incremental cost-effectiveness ratio (ICER) for facility HTC 
using 2015 WHO ART guidelines was US$226.85 (95%CrI:198.79-284.35) per quality-adjusted 
life year (QALY) gained. The strategy of facility HTC plus HIVST, using 2010 WHO ART 
guidelines, was extendedly dominated. The ICER for facility HTC plus HIVST, using 2015 WHO 
ART guidelines, was US$253.90 (95%CrI:201.71-342.02) per QALY gained compared with 
facility HTC and using 2015 WHO ART guidelines. 
 
Conclusions: HIVST may be cost-effective in a Malawian population with high HIV 
prevalence. HIVST is suited to an early HIV diagnosis and treatment strategy. 
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Introduction 
More than half of all people living with HIV (PLHIV), new HIV infections and HIV-related 
deaths are in East and Southern Africa [1]. Despite intensive efforts to meet 90-90-90 
UNAIDS testing, treatment and retention goals, nearly half of PLHIV remain unaware of their 
HIV status [2]. HIV testing and counselling (HTC) in health facilities is essential but remains 
underutilised [3]. Community-based HIV testing strategies have greater reach, but delivering 
these services remains costly, difficult to sustain, and can fail to offer satisfactory levels of 
privacy [4].  
 
HIV self-testing (HIVST) resolves many of these issues by enabling individuals to perform and 
interpret their own HIV test result in private [2], and can be delivered to communities safely 
and at low cost by trained volunteers [5, 6]. HIVST has achieves high population HTC uptake, 
especially amongst men, and good rates of linkage into HIV treatment [5]. However, no 
formal economic evaluation has been undertaken to inform policy makers in the region 
whether scaling-up self-testing offers efficient use of scare resources.  
   
Recently, a pragmatic cluster-randomised trial (CRT) was undertaken to investigate the 
impact of offering population-wide HIVST through community volunteers in Blantyre, 
Malawi (ISRCTN02004005) [5]. In this study, we undertook a cost-effectiveness analysis of 
this community-based HIVST intervention. We sought to use clinical effectiveness and 
economic data collected from participants of this trial [5, 7, 8], as well as data from 
secondary sources, and extrapolate the findings to the population-level and over longer time 
horizons than observed in the trial. We additionally explored the effects of changes in WHO 
and Malawian antiretroviral treatment (ART) initiation guidelines, which occurred after 
completion of the trial [9]. 
 
 
 
Methods 
Analytic overview 
We developed a microsimulation model to explore the impact of implementing HIVST in 
communities with high HIV prevalence and available facility-based HTC. The model simulates 
health provider and societal costs, and health consequences of acquiring HIV infection, HIV 
disease progression and initiation of ART. Simulating these costs and health consequences at 
the individual-level has the advantage that parameters (e.g. likelihood of accessing HIV 
testing) can reflect individual-level characteristics (e.g. age, sex). The model drew heavily 
upon evidence from the CRT [5]. 
 
HIV testing and treatment strategies  
During the CRT (February 2012 to August 2014), Malawi used the 2010 WHO ART guidelines, 
with ART initiated if the patient had CD4 counts <350 cells/mm3, was WHO stage 3 or 4, or 
was pregnant or breastfeeding [10]. Since August 2016, Malawi has used the 2015 WHO ART 
guidelines with ART offered to all HIV-positive individuals [9]. We therefore evaluated four 
strategies. The base-case was defined as (1) availability of facility HTC, using 2010 ART 
guidelines. We compared this strategy to: (2) availability of facility HTC plus HIVST, using 
2010 ART guidelines; (3) availability of facility HTC, using 2015 ART guidelines; and (4) 
availability of facility HTC plus HIVST, using 2015 ART guidelines. We did not consider the 
potential impact of other HIV prevention interventions. 
 
Decision-analytic model 
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Decision-analytic modeling used TreeAge Pro 2017 (TreeAge Software, Williamstown, 
Massachusetts). Figure 1 provides an overview of the model structure, which contained four 
health states; (1) HIV-negative; (2) HIV-positive and not on ART; (3) HIV-associated co-
morbidities; and (4) HIV-positive and on ART. Every month, individuals transitioned through 
these health states. The model records, and in some cases updates, certain characteristics 
including: sex; age; HIV status; CD4 count; WHO clinical stage; ART status; and months of 
ART received. These characteristics were used to estimate uptake of HIV testing; HIV 
incidence and prevalence; eligibility for ART initiation; risk of mortality; risk of HIV associated 
co-morbidities; and retention on ART.  
 
Characteristics of individuals 
Baseline population characteristics were estimated from the trial post-intervention survey in 
control clusters, showing 58% of participants were female; mean age 30 years; HIV 
prevalence ranged from 2.3% in 16-19 year old males to 28.6% in 40-49 year old females; 
2.1% HIV-positive with a CD4 count =<50 cells/μl and 36.6% HIV-positive with a CD4 count 
>500 cells/μl (Table 1).  
 
HIV testing and linkage into HIV care 
Trial data were used to derive probabilities for accessing each testing modality by sex and 
age [5]. Individuals who tested HIV-negative did not re-test for one year. In the trial, the 
HIVST service was provided independently of existing facility-based HTC; we therefore 
assumed mutually exclusive probabilities for accessing HIV testing modalities. Those who 
tested HIV-positive through HIVST incurred an additional cost for facility-based confirmatory 
HIV testing. A cohort study conducted before introduction of HIVST provided estimates of 
linkage into HIV treatment after facility HTC [11]. Linkage into HIV treatment after HIVST was 
based on trial findings [5]. For strategies including 2010 WHO ART guidelines, data from the 
literature were used to model the likelihood of those not eligible for ART returning for 
repeat assessment for ART initiation [12-17]. 
 
Transition probabilities 
Death occurred from HIV-related [18, 19] and unrelated causes, with Malawian specific age- 
and sex mortality rates used to model HIV-unrelated mortality [20]. HIV-negative individuals 
were at risk of acquiring HIV infection. As the model did not allow for interaction between 
individuals modeled [21], we assumed HIV incidence varied by age and sex but was 
otherwise constant and used estimates from a South African study with comparable ART 
coverage to Malawi [22].  
 
For HIV-positive individuals, a CD4 count was assigned on entry into the model or when 
infected with HIV. HIV-positive individuals’ CD4 counts decreased if not receiving ART, and 
increased if receiving ART [23], with rates of change estimated from previous studies [16, 19, 
24-27]. Modelled CD4 counts determined individual eligibility to start ART, and likelihood of 
HIV-associated co-morbidity or death. The model simulated progression to WHO clinical 
stages 3 or 4 [18] to account for ART eligibility under 2010 WHO guidelines. 
 
The model was parameterised to account for time-varying rates of ART discontinuation [28]. 
If treatment was discontinued, individuals returned to the “HIV-positive not on ART” health 
state. The model did not account for ART failure, or HIV viral load monitoring as this was not 
offered at the time of the trial. ART failure may require switching to more expensive second 
line ART regimens; however, this remains uncommon in the region [29]. 
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For HIV-associated co-morbidities, we only considered the costs and impact on health-
related quality of life (HRQoL) arising from hospitalisation [30]. For HIV-positive individuals 
not on ART, we multiplied the risk of experiencing these HIV associated co-morbidities [18, 
27] by the risk of hospitalisation [18]. For HIV-positive individuals on ART, we additionally 
multiplied these risks by the relative reduction in hospitalisation attributable to ART [31]. 
We assumed that HIV-positive individuals on ART who were hospitalised continued to take 
ART. We assumed individuals who experienced these co-morbidities would undergo HIV 
testing with a similar likelihood of linking into HIV treatment as after facility HTC. Additional 
information about the modelling approach (Appendix A), model parameter synthesis 
processes (Appendix B) and model external validation procedures (Appendix C) are provided 
in the appendices.  
 
Costs 
The direct health provider and societal costs of facility HTC, HIVST, assessment for ART 
eligibility, and ART were all derived from primary costing studies that recruited participants 
from the CRT [7, 8]. The costs associated with different HIV associated co-morbidities were 
derived from primary costing of adult medical admissions to the main public hospital in 
Blantyre [30]. Costs were adjusted to reflect the one-month cycle length used in the model. 
Societal costs incorporated estimates of direct health provider costs, direct non-medical 
costs and indirect costs. Table 2 shows the cost parameters in 2014 US dollars.  
 
Health-related quality of life 
The primary health outcome was quality-adjusted life years (QALYs), estimated by 
multiplying health utility scores assigned to the different health states in the model by the 
time spent in each health state, and summing across health states [32]. Utility scores varied 
by HIV status. For HIV-positive individuals, utility scores decreased as CD4 count decreased, 
and following HIV-associated co-morbidity [33, 34]. Utility scores for all health states were 
derived from primary economic studies in Blantyre that recruited participants from the CRT 
[7, 8], or from adult medical admissions [30]. In these studies the Chichewa version of the 
EuroQoL EQ-5D-3L [35] was used to assess HRQoL of participants. The EQ-5D utility scores 
for the health states were derived using the Zimbabwean [36] EQ-5D tariff set (Table 3).  
 
Cost-effectiveness analysis 
The model was used to project the costs and QALYs for each testing/ART strategy. A time 
horizon of 20 years rather than the standard lifetime horizon [32] was used, given likely 
changes in HIV incidence, and testing and treatment strategies over time. Scenario analyses 
included alternative time horizons of 10 and 40 years.  
 
Probabilistic sensitivity analysis (PSA) was used to address parameter uncertainty. The beta 
distribution was fitted to transition probabilities and health state utilities, and the gamma 
distribution for costs [37]. For each strategy, we ran 5,000 model runs, randomly selecting a 
value for each parameter from its distribution. For each model run, we estimated total costs 
and QALYs for a sample of 5000 individuals.  
 
We report mean discounted costs and QALYs per person across these simulations for each 
testing/ART strategy. We estimated the mean incremental cost and incremental QALYs by 
comparing the least costly and least effective strategy to the next least costly and least 
effective strategy. The incremental cost-effectiveness ratio (ICER) for respective 
comparators was calculated by dividing incremental costs by incremental QALYs gained. We 
excluded strategies that were dominated, i.e. less effective and more costly, or extendedly 
dominated, where the ICER for the strategy is higher than a more effective strategy. All 
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results are presented with 95% credible intervals (CrI). This interval represents the 2.5th and 
97.5th percentiles from the distribution of results from all simulations. Separate analyses 
were undertaken from health provider and societal perspectives [32]. Costs are represented 
in 2014 US and International dollars, and a discount rate of 3% was applied to both costs and 
health effects.  
  
We compared estimated ICERs against increasing cost-effectiveness thresholds: US$0/QALY; 
US$250/QALY; US$500/QALY; US$750/QALY. For each testing/ART strategy, we present the 
probability of cost-effectiveness at these thresholds. This probability represents the 
proportion of all simulations where the estimated ICER was below the specified cost-
effectiveness threshold [32]. As we compared multiple strategies, and because decision 
makers may have different cost-effectiveness thresholds, we also present cost-effectiveness 
acceptability frontiers (CEAF) [38] to show which strategy is optimal at increasing cost-
effectiveness thresholds. We undertook a series of deterministic sensitivity analyses, using 
the point estimate for all parameters except the one being explored, to evaluate the impact 
on the ICER. We estimated the ICERs across the plausible ranges for the parameter of 
interest and present findings in a tornado plot.   
 
 
Results 
Health provider costs 
Over a 20-year time horizon and health provider perspective, availability of facility HTC and 
using 2010 WHO ART guidelines was the least costly strategy (US$294.71 per person, 
95%CrI:270-318.45) (Table 4). The next least costly strategy was facility HTC and using 2015 
WHO ART guidelines (US$336.13 per person, 95%CrI:313.35-358.64). The two strategies of 
facility HTC plus HIVST, using either the 2010 or 2015 WHO ART guidelines, had higher mean 
discounted costs of US$380.27 (95%CrI:355.08-404.54) and US$438.79 (95%CrI:416.75-
461.12) per person, respectively.  
 
Societal costs 
Over a 20-year time horizon and societal perspective, facility HTC and using 2010 WHO ART 
guidelines was the least costly strategy (US$334.70 per person, 95%CrI:306.45-363.54). The 
next least costly strategy was facility HTC and using 2015 WHO ART guidelines (US$377.67 
per person, 95%CrI:351.29-405.16). The two strategies of facility HTC plus HIVST, using 
either the 2010 or 2015 WHO ART guidelines, had higher mean discounted societal costs of 
US$422.82 (95%CrI:392.19-452.10) and US$484.16 (95%CrI:456.30-512.96) per person, 
respectively.  
 
Health outcomes 
Over a 20-year time horizon, facility HTC and using 2010 WHO ART guidelines was the least 
effective strategy (11.64 QALYs per person, 95%CrI:11.43-11.86). The next least effective 
strategy was facility HTC and using 2015 WHO ART guidelines (11.82 QALYs per person, 
95%CrI:11.62-12.03). Facility HTC plus HIVST, using either the 2010 or 2015 WHO ART 
guidelines, were more effective, generating 11.99 (95%CrI:11.80-12.18) and 12.23 
(95%CrI:12.06-12.40) QALYs per person, respectively.  
 
Cost-effectiveness analyses 
From the health provider perspective and 20-year time horizon, the ICER for facility HTC and 
using 2015 WHO ART guidelines was US$226.85 (95%CrI:198.79-284.35) per QALY gained 
compared with facility HTC and using 2010 WHO ART guidelines (Table 4). The strategy of 
facility HTC plus HIVST and using 2010 WHO ART guidelines was extendedly dominated. The 
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ICER for facility HTC plus HIVST and using 2015 WHO ART guidelines was US$253.90 
(95%CrI:201.71-342.02) per QALY gained compared with facility HTC and using 2010 WHO 
ART guidelines. 
 
From the societal perspective and 20-year time horizon, the ICER for facility HTC plus HIVST 
and using 2015 WHO ART guidelines was US$234.69 (95%CrI:198.76-297.52) per QALY 
gained compared with facility HTC and using 2010 WHO ART guidelines. The strategy of 
facility HTC plus HIVST and using 2010 WHO ART guidelines was extendedly dominated. The 
ICER for facility HTC plus HIVST and using 2015 WHO ART guidelines was US$262.68 
(95%CrI:203.75-363.20) per QALY gained compared with facility HTC plus HIVST and using 
2010 WHO ART guidelines. Appendix D shows the findings when the costs were estimated in 
2014 International Dollars.  
 
Table 4 shows the probability that each strategy is cost-effective at cost-effectiveness 
thresholds of: US$0/QALY; US$250/QALY; US$500/QALY; US$750/QALY. Figure 2 shows the 
CEAF for the optimal strategies across increasing cost-effectiveness threshold values. Up to a 
threshold value of approximately US$200, the strategy of facility HTC and using 2010 WHO 
ART guidelines remained optimal in cost-effectiveness terms. At a cost-effectiveness 
threshold of US$250/QALY, the strategy of facility HTC and using 2015 WHO ART guidelines 
was optimal. At threshold values higher than approximately US$270, facility HTC plus HIVST 
and using 2015 WHO ART guidelines was the optimal strategy. 
 
Scenario analyses 
Over both the 10- and 40-year time horizons, the strategy of facility HTC plus HIVST and 
using 2015 WHO ART guidelines remained optimal at cost-effectiveness thresholds above 
US$500 per QALY (Table 5).  
 
Deterministic sensitivity analyses 
Figure 3 shows a tornado plot from the deterministic sensitivity analysis comparing the 
strategy of facility HTC plus HIVST and using 2015 WHO ART guidelines to the strategy of 
facility HTC and using 2015 WHO ART guidelines. The uptake of facility-based HIV testing and 
HIVST, cost of HIVST episode, and the HIV prevalence and incidence in the population had 
the greatest impact on the ICER. Appendix E provides more detail on the findings from the 
deterministic sensitivity analysis.  
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Discussion 
In this study, we undertook an economic evaluation of a community-based HIV self-testing 
service in Blantyre, Malawi, and estimated cost-effectiveness, taking into account recent 
changes in the guidelines for when individuals should start ART. Overall, we found that 
providing community-based HIVST and using the 2015 WHO ART guidelines was the optimal 
strategy at cost-effective thresholds above US$270/QALY. The gross domestic product in 
Malawi is approximately US$250 per capita. The finding that delivering HIV testing closer to 
people’s homes is cost-effective is not new [39]; however, to our knowledge, this is the first 
evaluation of HIVST strategies using robust data from a large cluster randomised trial, 
combined with primary economic studies. 
 
Adopting the 2015 WHO ART guidelines or implementing HIVST will result in higher 
healthcare costs. In Malawi, adopting the 2015 WHO ART guidelines would cost healthcare 
providers an additional US$41 per capita over the next 20 years, and would equate to a 14% 
increase in HIV testing and treatment expenditure. Adopting both strategies would cost 
US$144 per capita over the next 20 years and 49% increase in HIV testing and treatment 
expenditure, but implementation would have a synergistic effect, resulting in the greatest 
health gains. Uptake of HIV testing remains sub-optimal in the region [2], with HIV-positive 
individuals still only accessing HIV treatment services with advanced HIV disease [40]. 
Implementing HIVST may be necessary to achieve the hoped-for health benefits from 
universal access to ART, but needs to be balanced against local budgetary constraints and 
whether investing in other HIV and non-HIV interventions offers better value for money.    
 
We previously estimated the cost per individual tested through HIVST to be comparable to 
facility-based HTC [7]. The cost of HIVST kits is currently eight-times that of the rapid finger 
prick test kits used in health facilities. We found the cost of an HIVST episode and ART 
provision to be important drivers of cost-effectiveness. If the cost of an HIVST episode were 
lower, achievable if the cost of an HIVST kit fell from current estimates of $4 per kit, and the 
cost of ART provision lower, through lower ART drug costs, implementing HIVST and 
adopting the 2015 WHO ART guidelines would become more affordable for policymakers in 
the region. 
 
There are several limitations. Firstly, our analysis does not consider the impact of HIV 
transmission. In comparison to the base-case, the three other strategies examined resulted 
in a net gain in QALYs, as well as increased numbers on ART. As HIV infections averted 
depends on ART coverage amongst HIV-positive individuals, considereing HIV transmission is 
likely to have led to lower ICER estimates; therefore our findings represent conservative 
estimates. Secondly, we did not consider the impact of individuals failing ART. At the time of 
the trial, and health economic studies, HIV viral load monitoring was not routinely available 
in Malawi and only 3% of HIV-positive individuals in the region had switched to second-line 
ART regimens [29]. However, as all strategies examined result in more HIV-positive 
individuals taking ART, the need for HIV viral load monitoring and costlier second-line ART 
regimens will increase. This is likely to lead to less favorable ICERs than those estimated. 
Finally, we only considered the impact of HIV associated illnesses that required 
hospitalisations, and did not consider other illnesses which are managed in the community 
or at primary health clinics. Again, as the costlier strategies result in earlier initiation of ART, 
had we considered these additional health sequelae, the ICER estimates would likely have 
been lower.  
 
Achieving high coverage of ART is essential to eliminating the HIV epidemic in sub-Saharan 
Africa, but will require substantial increases in population rates of HIV testing. HIVST is 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix983/4609427
by Liverpool School of Tropical Medicine user
on 27 November 2017
  9 
popular and can have a major impact on population coverage of HIV testing with relatively 
little input from trained health professionals [5, 6]. We found implementing HIVST to be 
potentially cost-effective. Notably, our model suggests that the transition from restricted 
ART availability to the 2015 WHO ART guidelines of immediate offer of ART irrespective of 
CD4 count, combines favourably with HIVST. Without effective community HIV testing 
programmes, the health benefits of universal access to ART are limited by inability to detect 
early HIV efficiently under facility-only testing strategies. HIVST is therefore suited to an 
early HIV diagnosis and treatment strategy.   
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Figure 1: Overview of microsimulation model developed 
 
ART: Anti-retroviral treatment 
 
 
Figure 2: Cost-effectiveness acceptability frontier showing optimal strategy at 
increasing cost-effectiveness threshold values for gain in quality-adjusted life year 
 
ART: Anti-retroviral treatment  HTC: HIV testing and counselling   
HIVST: HIV self-testing  QALY: Quality-adjusted life year  
2010 WHO ART initiation guidelines: CD4 count <350 cells/mm3 or WHO stage 3 or 4 
2015 WHO ART initiation guidelines: start ART irrespective of CD4 count or WHO stage 
 
 
 
Figure 3: Tornado diagram showing findings from deterministic sensitivity analysis 
 
UV: Univariate/one-way sensitivity analysis  MV: Multivariate sensitivity analysis 
ART: Anti-retroviral treatment   HTC: HIV testing and counselling   
HIVST: HIV self-testing    ICER: Incremental cost-effectiveness ratio 
QALY: Quality-adjusted life year   KS: Kaposi’s sarcoma 
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Table 1: Overview of base-case model parameters 
 
Parameter 
 
 
Data 
 
Sources 
Individual characteristics 
Age and sex demographics 
HIV prevalence 
CD4 counts in HIV-positive 
 
58% female; mean age 30 years 
2.3-28.6% (age and sex dependent) 
36.6% CD4 count >500 cells/μl  
23.4% CD4 count 351-500 cells/μL 
22.8% CD4 count 201-350 cells/μl 
15.2% CD4 count 51-200 cells/μl 
2.1% CD4 count =<50 cells/μl 
 
Unpublished 
trial data (Post 
intervention 
survey) 
HIV testing and linkage into HIV care 
Annual uptake of facility HTC 
 
Annual uptake of HIVST 
Linkage after facility HTC 
Linkage after HIVST 
 
14.7-53.0% (age and sex dependent) 
 
40.8-99.9% (age and sex dependent) 
50.7% (95%CI: 44.9-56.6) 
41.7% (95%CI: 38.8-44.4) 
 
Unpublished 
trial data  
[5] 
[11] 
[5] 
HIV incidence and mortality  
HIV incidence 
 
Non-HIV mortality  
HIV mortality, not on ART 
 
HIV mortality, on ART 
 
0.66-6.49 per 100 person years (age and sex 
dependent)  
Malawi life tables (age and sex dependent) 
0.6-69.5 per 100 person years (CD4 count 
dependent) 
1.4-14.0 per 100 person years (CD4 count 
dependent) 
 
[22] 
 
[20] 
[18] 
 
[19] 
Mean change in CD4 count 
Not on ART 
 
On ART 
 
Decreases 4.0-5.7 cells/month (CD4 count 
dependent) 
Increases 1.3 cells/week (95%CI: 1.1-1.5) 
 
[16, 25-27] 
 
[19] 
HIV treatment outcomes 
Pre-ART returning for ART assessment in 6 
months 
Retention on ART 
 
57.1% (95%CI: 56.0, 58.0) 
 
0-6 months: 86.1% (95%CI: 84.6, 87.4) 
7-12 months: 80.2% (95%CI: 78.0, 82.4) 
13-24 months: 76.1% (95%CI: 72.4, 79.7) 
>24 months: 72.3% (95%CI: 67.4, 76.9) 
 
[12-17] 
 
[28] 
HIV-associated illnesses CD4 count dependent [18, 27] 
 
ART: Anti-retroviral treatment  HTC: HIV testing and counselling   
HIVST: HIV self-testing 
 
 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix983/4609427
by Liverpool School of Tropical Medicine user
on 27 November 2017
  17 
Table 2: Health provider and societal costs for model (2014 US)  
 
Cost Parameter 
2014 US Dollars Distribution 
Health provider costs  Societal costs 
Base case Low High  Base case Low High  
Facility-based HTC episode 8.90 7.53 10.57  10.68 9.91 11.45  
HIV self-testing episode 8.78 7.78 10.46  8.85 7.97 9.72  
Assessment for ART eligibility for all clients 22.27 21.32 23.21  25.46 24.14 26.79  
Annual cost of ART for facility HTC clients 168.65 164.69 172.62  181.91 175.38 188.45  
Annual cost of ART for facility HIVST clients 164.66 156.41 172.90  179.38 164.29 194.46 Gamma 
Cost of hospital 
admission for severe 
HIV associated illness 
Acute diarrhoea 300.97 134.37 467.56  481.56 190.30 772.82  
Chronic diarrhoea 233.06 93.84 372.28  372.28 114.42 407.39  
Oesophageal candidiasis 153.08 69.92 236.24  236.24 65.30 292.59  
Invasive bacterial diseases 223.45 199.68 247.21  247.21 229.39 291.01  
Pulmonary tuberculosis 437.68 339.02 536.33  536.33 441.79 716.81  
Extra-pulmonary tuberculosis 494.68 394.83 594.53  594.53 526.86 1014.00  
Malaria 199.63 106.55 292.72  292.72 69.06 647.84  
Malignancy (KS/Lymphoma) 242.92 195.53 290.31  290.31 244.64 389.41  
Pneumocystis Jivorecii pneumonia 325.56 268.15 382.97  382.97 294.62 495.67  
Cryptococcal meningitis 846.24 651.05 
1041.4
4 
 1041.44 760.87 1194.62  
HTC: HIV testing and counselling  ART: Anti-retroviral treatment 
HIVST: HIV self-testing   KS: Kaposi’s sarcoma 
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Table 3: EQ-5D utility scores for health states (Zimbabwean and UK tariff)  
 
Utility Parameters 
EQ-5D Utility scores 
Distribution Base 
case 
Low High 
HIV negative 1.000 1.000 1.000 
 
Beta 
HIV-positive not 
on ART 
 
CD4 >200 cells/μl 0.878 0.802 0.954 
CD4 51 to 200 cells/μl 0.840 0.762 0.917 
CD4 count <=50 cells/μl 0.654 0.558 0.749 
Increase over first year on ART for facility-HTC clients 0.129 0.107 0.150 
Increase over first year on ART for HIVST clients 0.139 0.087 0.192 
Hospital admission 
for severe HIV 
associated illness 
Acute diarrhea 0.367 0.143 0.590 
Chronic diarrhoea 0.476 0.316 0.636 
Oesophageal candidiasis 0.349 0.170 0.529 
Invasive bacterial diseases 0.499 0.457 0.541 
Pulmonary tuberculosis 0.429 0.349 0.509 
Extra-pulmonary tuberculosis 0.389 0.296 0.481 
Malaria 0.567 0.412 0.721 
Malignancy (KS/Lymphoma) 0.420 0.320 0.521 
Pneumocystis Jivorecii pneumonia 0.559 0.398 0.719 
Cryptococcal Meningitis 0.478 0.386 0.569 
HTC: HIV testing and counselling  ART: Anti-retroviral treatment 
HIVST: HIV self-testing   KS: Kaposi’s sarcoma 
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Table 4: Cost-effectiveness findings from primary analysis and 20 year time horizon (2014 US Dollars) 
Perspective HIV testing strategy 
ART initiation 
guideline 
Discounted mean costs and QALYs per person 
ICER 
**Probability cost-effective at cost-
effectiveness threshold (US$ per QALY) 
2014 US Dollars QALYs 
Mean cost 
(*95% CrI) 
Incremental 
cost 
(*95% CrI) 
Mean 
Effectiveness 
(*95% CrI) 
Incremental 
Effectiveness 
(*95% CrI) 
2014 US$ per QALY 
(*95% CrI) 
0 250 500 750 
Health 
Provider 
Facility HTC 2010 WHO ART 
294.71 
(270.79, 318.45) 
- 
11.64 
(11.43, 11.86) 
- - 1.000 0.128 0 0 
Facility HTC 2015 WHO ART 
336.13 
(313.35, 358.64) 
41.42 
(29.86, 55.64) 
11.82 
(11.62, 12.03) 
0.18 
(0.12, 0.25) 
226.85 
(198.79, 284.35) 
0 0.362 0.001 0 
Facility HTC & HIVST 2010 WHO ART 
380.27 
(355.08, 404.54) 
- 
11.99 
(11.80, 12.18) 
- ED*** 0 0.207 0 0 
Facility HTC & HIVST 2015 WHO ART 
438.79 
(416.75, 461.12) 
102.66 
(85.45, 120.04) 
12.23 
(12.06, 12.40) 
0.40 
(0.28, 0.53) 
253.90 
(201.71, 342.02) 
0 0.303 0.999 1.000 
Societal 
Facility HTC 2010 WHO ART 
334.70 
(306.45, 363.54) 
- 
11.64 
(11.43, 11.86) 
- - 1.000 0.178 0 0 
Facility HTC 2015 WHO ART 
377.67 
(351.29, 405.16) 
42.98 
(30.33, 58.84) 
11.82 
(11.62, 12.03) 
0.18 
(0.12, 0.25) 
234.69 
(198.76, 297.52) 
0 0.368 0.003 0 
Facility HTC & HIVST 2010 WHO ART 
422.82 
(392.19, 452.10) 
- 
11.99 
(11.80, 12.18) 
- ED*** 0 0.238 0.001 0 
Facility HTC & HIVST 2015 WHO ART 484.16 106.49 12.23 0.40 262.68 0 0.215 0.996 1.000 
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(456.30, 512.96) (84.90, 128.67) (12.06, 12.40) (0.28, 0.53) (203.75, 363.20) 
HTC: HIV testing and counselling  HIVST: HIV self-testing   ART: Anti-retroviral treatment  CrI; Credible interval 
QALYS: Quality-adjusted life years ICER: Incremental cost-effectiveness ratio ED: Extendedly dominated 
2010 WHO ART initiation guidelines: CD4 count <350 cells/mm
3
 or WHO stage 3 or 4 
2015 WHO ART initiation guidelines: start ART irrespective of CD4 count or WHO stage 
*95% CrI: represents the 2.5
th
 and 97.5
th
 percentile from the distribution of results from all the simulations 
**Probability represents the proportion of all simulations where the estimated ICER was below the specified cost-effectiveness threshold. Total may not add up to 1.0 as 
for some simulations, no single scenario was found most cost-effective at given cost-effectiveness threshold   
***Extended dominance: The ICER for this strategy higher than the next more effective strategy.     
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Table 5: Cost-effectiveness findings from the health provider perspective over different time horizons (2014 US Dollars) 
Time 
horizon 
HIV testing strategy 
ART initiation 
guideline 
Discounted mean costs and QALYs per person 
ICER 
**Probability cost-effective at cost-
effectiveness threshold (US$ per QALY) 
2014 US Dollars QALYs 
Mean cost 
(*95% CrI) 
Incremental 
cost 
(*95% CrI) 
Mean 
Effectiveness 
(*95% CrI) 
Incremental 
Effectiveness 
(*95% CrI) 
2014 US$ per QALY 
(*95% CrI) 
0 250 500 750 
10 years 
Facility HTC 2010 WHO ART 
157.77 
(142.53, 171.95) 
- 
7.45 
(7.35, 7.55) 
- - 1.000 0.998 0.031 0 
Facility HTC 2015 WHO ART 
184.86 
(172.07, 197.65) 
27.09 
(19.99, 36.41) 
7.52 
(7.42, 7.61) 
0.07 
(0.04, 0.10) 
389.43 
(311.05, 520.51) 
0 0 0.211 0.019 
Facility HTC & HIVST 2010 WHO ART 
206.82 
(190.24, 221.96) 
- 
7.56 
(7.47, 7.65) 
- ED*** 0 0.002 0.054 0.002 
Facility HTC & HIVST 2015 WHO ART 
247.64 
(234.64, 260.74) 
62.78 
(53.20, 72.58) 
7.67 
(7.58, 7.74) 
0.15 
(0.09, 0.20) 
430.47 
(323.11, 645.72) 
0 0 0.704 0.979 
20 years 
Facility HTC 2010 WHO ART 
294.71 
(270.79, 318.45) 
- 
11.64 
(11.43, 11.86) 
- - 1.000 0.128 0 0 
Facility HTC 2015 WHO ART 
336.13 
(313.35, 358.64) 
41.42 
(29.86, 55.64) 
11.82 
(11.62, 12.03) 
0.18 
(0.12, 0.25) 
226.85 
(198.79, 284.35) 
0 0.362 0.001 0 
Facility HTC & HIVST 2010 WHO ART 
380.27 
(355.08, 404.54) 
- 
11.99 
(11.80, 12.18) 
- ED*** 0 0.207 0 0 
Facility HTC & HIVST 2015 WHO ART 438.79 58.52 12.23 0.24 247.92 0 0.303 0.999 1.000 
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(416.75, 461.12) (44.32, 76.69) (12.06, 12.40) (0.16, 0.32) (207.60, 312.97) 
40 years 
Facility HTC 2010 WHO ART 
408.07 
(372.67, 445.05) 
- 
15.13 
(14.72, 15.55) 
- - 1.000 0 0 0 
Facility HTC 2015 WHO ART 
461.25 
(424.82, 498.46) 
- 
15.46 
(15.05, 15.88) 
- ED*** 0 0.007 0 0 
Facility HTC & HIVST 2010 WHO ART 
530.83 
(495.99, 565.74) 
122.77 
(99.18, 146.04) 
15.92 
(15.64, 16.28) 
0.79 
(0.55, 1.03) 
155.58 
(127.21, 204.37) 
0 0.033 0 0 
Facility HTC & HIVST 2015 WHO ART 
602.34 
(569.01, 635.77) 
71.51 
(51.89, 95.18) 
16.32 
(15.99, 16.66) 
0.41 
(0.24, 0.59) 
175.77 
(146.77, 236.34) 
0 0.960 1.000 1.000 
HTC: HIV testing and counselling  HIVST: HIV self-testing   ART: Anti-retroviral treatment CrI: Credible interval 
QALYS: Quality-adjusted life year  ICER: Incremental cost-effectiveness ratio ED: Extendedly dominated 
2010 WHO ART initiation guidelines: CD4 count <350 cells/mm
3
 or WHO stage 3 or 4 
2015 WHO ART initiation guidelines: start ART irrespective of CD4 count or WHO stage 
*95% CrI: represents the 2.5
th
 and 97.5
th
 percentile from the distribution of results from all the simulations 
**Probability represents the proportion of all simulations where the estimated ICER was below the specified cost-effectiveness threshold. *Total may not add up to 1.0 as 
for some simulations, no single scenario was found most cost-effective at given cost-effectiveness threshold   
***Extended dominance: The ICER for this strategy higher than the next more effective strategy.     
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Figure 1. 
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Figure 2. 
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Figure 3. 
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